BioCorRx Expands Pharmaceutical Portfolio with LUCEMYRA® Acquisition, Signals Strategic Growth in Addiction Treatment

BioCorRx Inc. has strategically positioned itself in the addiction treatment market through the acquisition of LUCEMYRA® (lofexidine), a unique non-opioid medication designed to mitigate opioid withdrawal symptoms. The pharmaceutical company's first-quarter financial results reveal substantial potential for this strategic asset acquisition.

The company reported net product revenues of $134,899 from LUCEMYRA® in the first quarter of 2025, a significant increase from $3,620 in the same period in 2024. Simultaneously, BioCorRx has managed to reduce operating expenses by approximately 9%, demonstrating fiscal prudence and strategic financial management.

Beyond the LUCEMYRA® acquisition, BioCorRx continues to develop innovative treatment solutions for substance use disorders. The company is advancing research on BICX104, a subcutaneous naltrexone implantable pellet targeting methamphetamine use disorder (MUD). This research is supported by a substantial grant from the National Institutes of Health's National Institute on Drug Abuse.

The development of BICX104 is particularly crucial given the significant public health challenges posed by methamphetamine addiction. Recent data indicates that over 16.6 million people have used methamphetamine at least once in their lifetime, underscoring the urgent need for effective treatment options.

By expanding its pharmaceutical portfolio and maintaining a focused approach to addiction treatment, BioCorRx is positioning itself as a potential leader in addressing complex substance use disorders. The company's comprehensive strategy, which includes medication-assisted treatments and cognitive behavioral therapy modules, represents a holistic approach to addiction recovery.

As the global healthcare landscape continues to evolve, BioCorRx's investments in innovative treatment solutions could play a critical role in addressing the growing challenges of substance use disorders and supporting patients' recovery journeys.